# Crinetics Pharmaceuticals, Inc. · Edgar & Edgarette company card

> Crinetics Pharmaceuticals grew revenue 641% in FY2025 to $8 million, operating margin -6715% against a -3.8% median for pharmaceutical preparations, equity 88.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1658247 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/1658247) · [JSON](https://www.pops4.com/boards/company/1658247.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $8M |
| Revenue growth, 1 year | 640.7% |
| Revenue growth per year | 63.5% |
| Operating margin | -6714.8% (prior year -32613.5%) |
| Net margin | -6046.2% |
| Operating cash flow | −$378M |
| Capital spending | $6M |
| Free cash flow | −$384M |
| Cash | $102M |
| Long-term debt | — |
| Total assets | $1.1B |
| Total equity | $992M |
| Equity ÷ assets | 88.1% |
| Return on equity | -46.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 6.19 (safe zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: null (above the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed auditor change in the last 12 months; operating cash flow was negative; operating loss: a margin of -6714.8% in FY2025; revenue is hard to predict: its 80% range is ±75%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $7.7M (FY2025). Experience: revenue up 640.7% on the year, up 63.5% a year over 4 years; operating margin -6714.8%, up from -32613.5%. Soundness: equity 88.1% of assets, return on equity -46.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $12.5M and $85.5M next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $10.9M to $98.0M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -6714.8% against a -3.8% median; growth 640.7% against 13.7%.

Range logged 2026-09-29, receipt ea74c91fc9ed237d, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2026-09-01 ([filing](https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-03-03 ([filing](https://www.sec.gov/Archives/edgar/data/1658247/000165824726000017/0001658247-26-000017-index.htm))
- Item 5.02 Director or officer change: 6, latest 2026-09-01 ([filing](https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm))

## Recent filings

- 8-K · filed 2026-09-01 · 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 3.03 Material Modifications to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1658247/000114036126035195/0001140361-26-035195-index.htm)
- 8-K · filed 2026-08-28 · 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1658247/000114036126034857/0001140361-26-034857-index.htm)
- 8-K · filed 2026-08-19 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1658247/000114036126033738/0001140361-26-033738-index.htm)
- 8-K · filed 2026-08-14 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1658247/000114036126032951/0001140361-26-032951-index.htm)
- 10-Q · filed 2026-08-03 · [filing](https://www.sec.gov/Archives/edgar/data/1658247/000165824726000053/0001658247-26-000053-index.htm)
- 8-K · filed 2026-08-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1658247/000165824726000052/0001658247-26-000052-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001658247.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1658247

## Cite

POPS4, Edgar & Edgarette: Crinetics Pharmaceuticals, Inc. company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/1658247. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.